02:06:10 EDT Tue 04 Aug 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:SPRO from 2019-08-05 to 2020-08-04 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2020-07-31 17:04U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-29 16:01U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
2020-06-30 17:19U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-08 18:40U:SPRONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO
2020-06-03 16:26U:SPRONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO
2020-06-01 08:15U:SPRONews ReleaseSpero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
2020-06-01 07:45U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-28 13:58U:SPRONews ReleaseSPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
2020-05-27 08:48U:SPRONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO
2020-05-13 11:12U:SPRONews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of  Spero Therapeutics, Inc. - SPRO
2020-05-08 08:05U:SPRONews ReleaseSpero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update
2020-05-05 16:01U:SPRONews ReleaseSpero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection
2020-05-04 08:00U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020
2020-04-30 18:59U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-04-16 08:30U:SPRONews ReleaseSpero Announces Appointment of Scott Jackson to its Board of Directors
2020-03-31 16:45U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-03-16 08:45U:SPRONews ReleaseSpero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
2020-03-11 08:30U:SPRONews ReleaseSpero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
2020-03-05 16:01U:SPRONews ReleaseSpero Therapeutics Announces Closing of Rights Offering
2020-02-28 17:00U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-02-26 16:00U:SPRONews ReleaseSpero Therapeutics to Present at March Investor Conferences
2020-02-11 08:00U:SPRONews ReleaseSpero Therapeutics Announces Commencement of Rights Offering
2020-02-05 08:00U:SPRONews ReleaseSpero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
2020-01-31 18:55U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-01-30 08:00U:SPRONews ReleaseSpero Therapeutics Announces Proposed Rights Offering
2020-01-13 08:00U:SPRONews ReleaseSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and  Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
2019-12-04 16:01U:SPRONews ReleaseSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces  Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
2019-11-29 15:45U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-26 08:30U:SPRONews ReleaseSpero Therapeutics to Host Key Opinion Leader Symposium in December
2019-11-04 16:05U:SPRONews ReleaseSpero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review
2019-10-31 17:08U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-10-03 08:00U:SPRONews ReleaseSpero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
2019-09-30 17:00U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-26 08:30U:SPRONews ReleaseSpero Therapeutics Announces Presentations at IDWeek 2019
2019-08-08 16:10U:SPRONews ReleaseSpero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update